Adaptive Biotechnologies Corp
ADPT12.470USD
-0.570-4.37%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.90BCap. mercado
PérdidaP/E TTM
Más Datos de Adaptive Biotechnologies Corp Compañía
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Información de la empresa
Símbolo de cotizaciónADPT
Nombre de la empresaAdaptive Biotechnologies Corp
Fecha de salida a bolsaJun 27, 2019
Director ejecutivoMr. Chad M. Robins
Número de empleados619
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 27
Dirección1165 Eastlake Ave E
CiudadSEATTLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal98109
Teléfono12066590067
Sitio Webhttps://www.adaptivebiotech.com
Símbolo de cotizaciónADPT
Fecha de salida a bolsaJun 27, 2019
Director ejecutivoMr. Chad M. Robins
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-3.91%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
MRD revenue
43.72M
83.37%
Immune meidicine revenue
8.72M
16.63%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
MRD revenue
43.72M
83.37%
Immune meidicine revenue
8.72M
16.63%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Nikko Asset Management Co., Ltd.
2.82%
Otro
58.71%
Accionistas
Accionistas
Proporción
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Nikko Asset Management Co., Ltd.
2.82%
Otro
58.71%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
46.73%
Investment Advisor
34.42%
Hedge Fund
13.47%
Individual Investor
2.65%
Research Firm
2.14%
Private Equity
0.68%
Venture Capital
0.45%
Bank and Trust
0.31%
Pension Fund
0.26%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
498
148.68M
97.64%
-4.69M
2025Q1
498
156.30M
102.90%
-1.29M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
2023Q1
577
135.96M
94.24%
-11.97M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Viking Global Investors LP
29.99M
19.74%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.12M
7.32%
+428.54K
+4.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.79M
6.45%
-19.96K
-0.20%
Mar 31, 2025
Rubric Capital Management LP
13.12M
8.63%
-1.48M
-10.15%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
6.09M
4.01%
-747.45K
-10.94%
Mar 31, 2025
ARK Investment Management LLC
4.40M
2.9%
-1.67M
-27.51%
May 31, 2025
Braidwell LP
4.80M
3.16%
+4.80M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
2.78M
1.83%
+96.32K
+3.59%
Mar 31, 2025
State Street Global Advisors (US)
2.69M
1.77%
-40.36K
-1.48%
Mar 31, 2025
Aristotle Atlantic Partners, LLC
2.94M
1.94%
+54.51K
+1.89%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
4.49%
Franklin Genomic Advancements ETF
2.06%
ROBO Global Healthcare Technology & Innovation ETF
1.91%
Invesco Dorsey Wright Industrials Momentum ETF
1.14%
First Trust Small Cap Growth AlphaDEX Fund
0.86%
Even Herd Long Short ETF
0.69%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.68%
Invesco NASDAQ Future Gen 200 ETF
0.55%
First Trust Small Cap Core Alphadex Fund
0.47%
Invesco Dorsey Wright SmallCap Momentum ETF
0.47%
Ver más
ARK Genomic Revolution ETF
Proporción4.49%
Franklin Genomic Advancements ETF
Proporción2.06%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.91%
Invesco Dorsey Wright Industrials Momentum ETF
Proporción1.14%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.86%
Even Herd Long Short ETF
Proporción0.69%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.68%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.55%
First Trust Small Cap Core Alphadex Fund
Proporción0.47%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.47%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
